## Bone Grafting Versus Non-Grafting In Management of Benign Bony Cystic Lesions

## A Comparative Study

#### **Thesis**

Submitted for partial fulfillment of M.D. degree in Orthopaedic Surgery

By

#### **Mohamed Ahmed Ahmed El Mowafi**

M.B.B Ch, M.Sc. Orthopaedic Surgery Faculty of Medicine, Ain Shams University

#### Supervised by

#### Prof. Dr. Ezzat Mohamed El Hawi

Professor of Orthopaedic Surgery Faculty of Medicine, Ain Shams University

#### **Prof. Dr. Mohamed Abdel Rahman Mostafa**

Professor of Orthopaedic Surgery Faculty of Medicine, Ain Shams University

### **Dr. Sherif Ishak Azmy**

Lecturer of Orthopaedic Surgery Faculty of Medicine, Ain Shams University

Faculty of Medicine
Ain Shams University
2018



# Acknowledgement

First of all, I would like to express my deep gratitude to **ALLAH** for his care and generosity throughout my life.

I would like to express my sincere appreciation to **Prof. Dr. Ezzat**Mohamed El Hawi, Professor of Orthopaedic Surgery, Faculty of

Medicine—Ain Shams University, for his keen supervision, guidance and his

overwhelming support that has been of great help throughout this work. I

really have the honor to complete this work under his supervision.

No words can express my deepest gratitude, thanks and gratefulness to **Prof.Dr. Mohamed Abdel Rahman Mostafa**, Professor of Orthopaedic Surgery, Faculty of Medicine –Ain Shams University, for his enthusiastic support, continuous encouragement, valuable scientific advices, and great help through out of the accomplishment of this work. It would be impossible to count all the ways that he has helped me to operate most of cases of this study.

I would like to express my deep thanks to **Dr. Sherif Ishak Azmy,** Lecturer of Orthopaedic Surgery, Faculty of Medicine –Ain Shams
University, for his sincere help, encouragement, continuous guidance and valuable advice.

To my beloved family for all support they have given to me.

Mohamed Ahmed El Mowafi

## **List of Contents**

| Subject               | Page No. |
|-----------------------|----------|
| List of Abbreviations | i        |
| List of Tables        | iii      |
| List of Figures       | v        |
| List of Cases         | viii     |
| Introduction          | 1        |
| Aim of the Work       | 4        |
| Review of Literature  | 5        |
| Patients and Methods  | 73       |
| Results               | 112      |
| Case Presentation     | 131      |
| Discussion            | 153      |
| Conclusion            | 166      |
| Summary               | 170      |
| References            | 175      |
| Arabic Summary        | <b>—</b> |

#### **List of Abbreviations**

## Abbr. Full-term

**AATB** : American Association of Tissue Banks

**ABC** : Aneurysmal bone cyst

**ASIS** : Anterior superior iliac spine

**BMPs** : Bone morphogenetic proteins

**CT** : Computed tomography

**DFDBA** : Demineralized freeze dried bone allograft

**DVT** : Deep venous thrombosis

**FD** : Fibrous dysplasia

**FDA** : Food and Drug Administration

**GCT** : Giant cell tumor

 $\mathbf{H_2O_2}$ : Hydrogen peroxide

**HBV** : Hepatitis B virus

**HCV** : Hepatitis C virus

**HS** : Highly significant

**HTLV** : Human T-cell lymphotrophic virus

**MP** : Middle phalanx

**MRI** : Magnetic resonance imaging

MTSRS : Musculoskeletal Tumor Society Rating Score

NS : Non-significant

**PMMA** : Polymethylmethacrylate

**PP** : Proximal phalanx

**PSIS** : Posterior superior iliac spine

S : Significant

**SBC** : Simple bone cyst

SI : Sacro-iliac

## **List of Tables**

| . Title  | Page No.   |
|--|--|
| Comparative properties of grafts                     | 34   |
| Demographic data of group A (grafti group)           | _  |
| Demographic data of group B (non-group)              | _  |
| Statistical analysis of the demograph of group A     |  |
| Statistical analysis of the demograph of group B     |  |
| Modified Neer's classification of rad healing status | O  |
| Operative data of group A                            | 110  |
| Operative data of group B                            | 111  |
| Analysis of the operative data of both groups        |  |
| Upper limb MSTS score                                | 112  |
| Lower limb MSTS score                                | 113  |
| MSTS score for cases of grafting group A)            |  |
| MSTS score for cases of non-grafting group (group B) |  |
| Functional results of the two groups.                | 115  |
| Summary of complications in both g                   | roups 122  |
|  | Comparative properties of grafts  Demographic data of group A (grafti group) |

| <b>Table (16):</b> | Patient sex in both groups                            | 122 |
|--------------------|---|-----|
| <b>Table (17):</b> | Lesion side in both groups                            | 123 |
| <b>Table (18):</b> | Pathological diagnosis in both groups                 | 123 |
| <b>Table (19):</b> | Anatomical site of lesion in both groups              | 124 |
| <b>Table (20):</b> | Osteosynthesis in both groups                         | 126 |
| <b>Table (21):</b> | Use of drain in both groups                           | 126 |
| ` '                | Intra-operative complications in both groups          | 127 |
| ` '                | Modified Neer's classification in both groups         | 128 |
|                    | Post-operative complications in both groups           | 129 |
| <b>Table (25):</b> | The need for 2 <sup>ry</sup> procedure in both groups | 129 |
| <b>Table (26):</b> | Pearson Correlation Test:                             | 130 |

## **List of Figures**

| . Title  | Page   | No.                                 |
|--|--|-------------------------------------|
| Different types of surgical margins                                | •••••  | 10                                  |
| Margins of resection of bone tumors.                               |  | 11                                  |
| Adjuvants used in extended curettage                               | )  | 13                                  |
| Peripheral sources of cancellous bone                              | e graft  | 42                                  |
| 2 1  |  |                                     |
| Harvesting of nonvascularized fibular                              | r graft  | 45                                  |
| illustrating the thickness of the posteriorly and the amount of ca | e ilium<br>incellous   |                                     |
| oblique posterior ilium with defect                                | in iliac   |                                     |
| Haevesting posterior iliac graft                                   | •••••  | 48                                  |
| <b>C</b>   |  |                                     |
| •  |  |                                     |
|  |  |                                     |
|  |  |                                     |
| age in our study   | •  |                                     |
|  | Different types of surgical margins  Margins of resection of bone tumors.  Adjuvants used in extended curettage Peripheral sources of cancellous bone Harvesting of proximal tibiai & grafts  Harvesting of nonvascularized fibular  CT scan of the pelvis at the level of illustrating the thickness of the posteriorly and the amount of ca bone available | Different types of surgical margins |

| <b>Figure (15):</b> | Patients distribution according to sex in our study  |
|---------------------|--|
| <b>Figure (16):</b> | Pie chart showing group A data about the types of tumors resected                            |
| Figure (17):        | Pie chart showing group B data about the types of tumors resected                            |
| <b>Figure (18):</b> | Pie chart showing anatomical sites in group A  |
| Figure (19):        | Pie chart showing anatomical sites in group B  |
| <b>Figure (20):</b> | Side of the lesion in both groups 81   |
| Figure (21):        | Various locations of the tumor detected by PXR in our study                                  |
| <b>Figure (22):</b> | CT of a case of distal tibial ABC in our study 90  |
| <b>Figure (23):</b> | Characteristic MRI finding of fluid-fluid levels in a case of distal ulna ABC in our study91 |
| Figure (24):        | Opening bone window for curettage 102  |
| <b>Figure (25):</b> | Use of highspeed burr in extended curettage 102  |
| <b>Figure (26):</b> | Use of H <sub>2</sub> O <sub>2</sub> in extended curettage                                   |
| <b>Figure (27):</b> | Use of electrocautery to eradicate remaining tumor cells                                     |
| <b>Figure (28):</b> | Adjuvants use in our study 104   |
| <b>Figure (29):</b> | Harvested grafts in our study 105  |
| <b>Figure (30):</b> | Mean of cavity volume in both groups (in cm <sup>3</sup> ) 106                               |
| <b>Figure (31):</b> | Mean of operative time in both groups (in hours)   |
| <b>Figure (32):</b> | Osteosynthesis in both groups  |
|                     |  |

## List of Figures

| <b>Figure (33):</b> | Use of surgical drain in both groups 108                      |
|---------------------|---|
| <b>Figure (34):</b> | Incidence of intra operative complications in both groups     |
| <b>Figure (35):</b> | Mean of MTSRS percentage                                      |
| <b>Figure (36):</b> | Mean of follow up period in both groups (in years)            |
| <b>Figure (37):</b> | Modified Neer's classification of cyst healing in both groups |
| Figure (38):        | Mean of percent of cavity filling in CT measurements          |
| <b>Figure (39):</b> | Post-operative complications in both groups 121               |
| <b>Figure (40):</b> | The need for $2^{ry}$ procedure in both groups 121            |

## **List of Cases**

| Case No.            | Title        | Page No. |
|---------------------|--------------|----------|
| Case (1): (Grafting | group)       | 132      |
| Case (2): (Grafting | group)       | 137      |
| Case (3): (Non-Gra  | fting group) | 144      |
| Case (4): (Non-Gra  | fting group) | 149      |

## Introduction

The majority of the benign cystic bone tumors are treated adequately by curettage. (1) Compared with resection, curettage is associated with a higher rate of local recurrence; however, curettage often allows for a better functional result. (1) Curettage can be extended by the use of adjuvants, such as liquid nitrogen, phenol, polymethylmethacrylate (PMMA), or thermal cauterization to extend the destruction of tumor cells. (2) Therefore benign bone tumors are often treated with intralesional curettage, which creates a bone defect. (3)

The management of benign bony defects has been the subject of much debate between orthopeadic surgeons in recent years. (4) There has been an increasing trend towards intra-operative filling of these lesions, especially when dealing with defects in weight-bearing areas, aiming to increase final bone strength and, especially for giant cell tumor (GCT), to reduce the risk of local recurrence. (4)

Available options to fill benign bone defects include autologous bone grafts<sup>(5)</sup>, allografts<sup>(6)</sup>, PMMA bone cement<sup>(7)</sup>, demineralized bone matrix and bone graft substitutes.<sup>(8)</sup>

The auto grafts have limited availability, donor site morbidity, cosmetic problems and more blood loss. (9) Allograft is an attractive alternate to autogenous bone as it

avoids donor site morbidity and its relative abundance permits it to be tailored to fit the defect size. (10) However, risk of infection, disease transmission and rejection of foreign body is associated with the use of allograft. (9)

PMMA cement may provide instant stability, but it is not the most biological method for filling of bone. There is concern that when used near the surface of a joint, it may cause thermal injury and damage to chondrocytes leading to secondary osteoarthritis.

As regards bone substitutes, there is very little evidence for their efficacy and there have been very few comparisons with the normal degree of healing expected in bone defects. (13)

Despite the fact that there is a strong capacity to create new bone after trauma, there have been very few studies reporting on the ability of a surgically created bone defect to fill in if left empty.<sup>(14)</sup>

Enchondroma in the hand or foot can be successfully treated without filling.<sup>(15)</sup> However, Chigira et al. curetted benign bone tumors in different locations without filling and, even in large defects, they found bone remodeling with sufficient strength for daily activity.<sup>(16)</sup> Waldram & Sneath

stated that bone grafting is not necessarily required after curettage of a giant cell tumor. (17)

In benign cystic lesions and giant cell tumors of bone treated by curettage and without filling with bone graft or other substitute, the hematoma in the cavity has strong capacity to create new bone and remodel with sufficient strength for daily activity.<sup>(4)</sup>

The paucity of data on the natural history of bone defects aroused our interest to do this comparative study to assess the efficacy of curettage of benign bony lesions without grafting versus the conventional grafting.